Fleming Pharmaceuticals Increases Supply of Nuclear Radiation Safeguard

April 22, 2011
Implemented manufacturing changes to move from made-to-order to mass production

Fleming Pharmaceuticals, maker of ThyroShield the only FDA approved liquid potassium iodide product indicated for thyroid protection in radiation emergencies -- announced on April 21 that it has is now able to ramp up production to meet increased domestic and international demand.

ThyroShield is an over-the-counter iodide solution which, when taken orally, saturates the thyroid gland so radioactive iodine cannot be absorbed.

"ThyroShield was developed under the Orphan Drug Act - a federal law designed to encourage the development of pharmaceuticals that have limited commercial potential," explains Phill Dritsas, president of Fleming Pharmaceuticals."It has always been made-to-order, rather than produced in mass quantities like other, more common over-the-counter medications. With the production changes we've implemented over the past six weeks, we are confident that we can now fulfill increase in demand for the product."

Working closely with the FDA, the company has qualified a new potassium iodide (KI) supplier to ensure a steady supply of quality raw materials to manufacture ThyroShield. The company has also established new agreements with vendors to shorten lead times needed to complete orders for package components such as bottles, caps and droppers. Finally, Fleming Pharmaceuticals has completed a thorough audit to identify production line logistics that can be immediately implemented to fulfill any significant new orders.

See Also
Fleming Pharmaceuticals Stepping Up Production of Nuclear Antidote

Sponsored Recommendations

Voice your opinion!

To join the conversation, and become an exclusive member of IndustryWeek, create an account today!